Boston, MA 02\/26\/2014 (wallstreetpr) – <\/b>VIVUS, Inc. (NASDAQ:VVUS)<\/b> was source of bad news on Nasdaq as the company preferred silence to addressing the concerns around its obesity drug Qsymia. The stock fell more than 15 percent in early trading Tuesday and ended up touching a new 52-week low by bell time. The drug was once viewed as having great revenue potential for the company and everyone from the management to investors and analysts were excited when it launched about 18 months ago. Yet, its blockbuster potentials have apparently not exploited and the company doesn\u2019t seem to be doing enough to boost sales. There have been attempts by VIVUS, Inc. (NASDAQ:VVUS) to orchestrate partnership in order to attain full commercialization of the drug, but such efforts are not progressing at the desired pace. So then, analysts at JPMorgan Chase & Co (NYSE:JPM)<\/b> didn\u2019t spare their view and ended up downgrading the stock of VIVUS, Inc. (NASDAQ:VVUS) to \u201cneutral,\u201d initially they have \u201coverweight\u201d tag on the stock.<\/p>\n
Prospect Capital Corporation (NASDAQ:PSEC)<\/b> begins ex-dividend trading Wednesday, February 26. The company recently declared cash dividend of 0.11035 per share, an amount that will be paid out to investors on March 20. Investors who acquired the stock before the ex-dividend date would partake in the declared cash payment. The latest dividend reflects 0.02 percent increase from what was offered in the prior month. With the stock of PSEC trading around $11.03 per share, the new dividend yield is about 11.70 percent. Currently PSEC has earnings per share of $1.15. The stock of Prospect Capital Corporation (NASDAQ:PSEC) ended the previous session at $11.03 per share after almost 3 percent of its value evaporated in the day.<\/p>\n
EMC Corporation (NYSE:EMC)<\/b> which recently had its \u201cbuy\u201d rating reaffirmed by TheStreet was lacking on the positive side of things in the previous session. The company lost a cent per share to hit $25.68, thus reflecting 0.04 percent south deviation from the previous closing price. While recommending EMC for \u201cbuy\u201d, TheStreet observed that the stock had increasing net income, good cash flow, revenue growth and attractive profit margins among other positive attributes.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 02\/26\/2014 (wallstreetpr) – VIVUS, Inc. (NASDAQ:VVUS) was source of bad news on Nasdaq as the company preferred silence to addressing the concerns around […]<\/p>\n","protected":false},"author":2,"featured_media":15971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264,4085],"tags":[2173,1628,1360,2091,753,603,4742,2090],"stock_ticker":[],"class_list":["post-16020","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","category-analyst-reports-on-stocks","tag-emc-corporation-nyseemc","tag-jpmorgan-chase-co-nysejpm","tag-nasdaqpsec","tag-nasdaqvvus","tag-nyseemc","tag-nysejpm","tag-prospect-capital-corporation-nasdaqpsec","tag-vivus-inc-nasdaqvvus","entry"],"acf":[],"yoast_head":"\n